Did you know that around 15% of children (3 - 17 years) in the US are reported with neurodevelopment disabilities? These include autism, attention deficit hyperactivity disorder, and other developmental delays. Neurodevelopmental and neuropsychiatric disorders (such as autism spectrum disorder) have broad health implications for children, with no definitive cure for the vast majority of them.
One recent review has shown that there is a strong body of evidence suggests early CBD treatment may offer significant potential to safely relieve many of the common symptoms affecting children with neurodevelopmental disorders. Clinical studies of CBD therapy in autism have demonstrated a positive response in irritability, hyperactivity, and anxiety. Other trials are underway for anxiety/behavioural outcomes in Tourette’s syndrome. Positive results have also been obtained in case studies and clinical trials in children in Fragile X syndrome. This review also suggests that CBD is currently the most promising therapeutic cannabinoid for children due to its safety profile and broad-spectrum action.
Reference:
Kwan Cheung, K. A., Mitchell, M. D. & Heussler, H. S. Cannabidiol and Neurodevelopmental Disorders in Children. Front. Psychiatry 12, (2021). https://www.frontiersin.org/articles/10.3389/fpsyt.2021.643442/full
